436 related articles for article (PubMed ID: 24861084)
1. Lipid biology of the podocyte--new perspectives offer new opportunities.
Fornoni A; Merscher S; Kopp JB
Nat Rev Nephrol; 2014 Jul; 10(7):379-88. PubMed ID: 24861084
[TBL] [Abstract][Full Text] [Related]
2. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.
Fornoni A; Sageshima J; Wei C; Merscher-Gomez S; Aguillon-Prada R; Jauregui AN; Li J; Mattiazzi A; Ciancio G; Chen L; Zilleruelo G; Abitbol C; Chandar J; Seeherunvong W; Ricordi C; Ikehata M; Rastaldi MP; Reiser J; Burke GW
Sci Transl Med; 2011 Jun; 3(85):85ra46. PubMed ID: 21632984
[TBL] [Abstract][Full Text] [Related]
3. Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes.
Ahmad A; Mitrofanova A; Bielawski J; Yang Y; Marples B; Fornoni A; Zeidan YH
FASEB J; 2017 Feb; 31(2):771-780. PubMed ID: 27836988
[TBL] [Abstract][Full Text] [Related]
4. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.
Yoo TH; Pedigo CE; Guzman J; Correa-Medina M; Wei C; Villarreal R; Mitrofanova A; Leclercq F; Faul C; Li J; Kretzler M; Nelson RG; Lehto M; Forsblom C; Groop PH; Reiser J; Burke GW; Fornoni A; Merscher S
J Am Soc Nephrol; 2015 Jan; 26(1):133-47. PubMed ID: 24925721
[TBL] [Abstract][Full Text] [Related]
5. Sphingomyelin Phosphodiesterase Acid-Like 3b is Essential for Toll-Like Receptor 3 Signaling in Human Podocytes.
Watanabe S; Hidenori U; Hashimoto S; Riko S; Aizawa T; Tsugawa K; Imaizumi T; Tanaka H
J Membr Biol; 2022 Feb; 255(1):117-122. PubMed ID: 34739556
[TBL] [Abstract][Full Text] [Related]
6. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis.
Ge M; Molina J; Ducasa GM; Mallela SK; Varona Santos J; Mitrofanova A; Kim JJ; Liu X; Sloan A; Mendez AJ; Banerjee S; Liu S; Szeto HH; Shin MK; Hoek M; Kopp JB; Fontanesi F; Merscher S; Fornoni A
Hum Mol Genet; 2021 Apr; 30(3-4):182-197. PubMed ID: 33517446
[TBL] [Abstract][Full Text] [Related]
7. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
[TBL] [Abstract][Full Text] [Related]
8. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
[TBL] [Abstract][Full Text] [Related]
9. Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.
Pedigo CE; Ducasa GM; Leclercq F; Sloan A; Mitrofanova A; Hashmi T; Molina-David J; Ge M; Lassenius MI; Forsblom C; Lehto M; Groop PH; Kretzler M; Eddy S; Martini S; Reich H; Wahl P; Ghiggeri G; Faul C; Burke GW; Kretz O; Huber TB; Mendez AJ; Merscher S; Fornoni A
J Clin Invest; 2016 Sep; 126(9):3336-50. PubMed ID: 27482889
[TBL] [Abstract][Full Text] [Related]
10. APOL1 localization in normal kidney and nondiabetic kidney disease.
Madhavan SM; O'Toole JF; Konieczkowski M; Ganesan S; Bruggeman LA; Sedor JR
J Am Soc Nephrol; 2011 Nov; 22(11):2119-28. PubMed ID: 21997392
[TBL] [Abstract][Full Text] [Related]
11. Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy.
Johnstone DB; Zhang J; George B; Léon C; Gachet C; Wong H; Parekh R; Holzman LB
Mol Cell Biol; 2011 May; 31(10):2162-70. PubMed ID: 21402784
[TBL] [Abstract][Full Text] [Related]
12. Podocyte pathology and nephropathy - sphingolipids in glomerular diseases.
Merscher S; Fornoni A
Front Endocrinol (Lausanne); 2014; 5():127. PubMed ID: 25126087
[TBL] [Abstract][Full Text] [Related]
13. TRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseases.
Ilatovskaya DV; Staruschenko A
Am J Physiol Renal Physiol; 2015 Sep; 309(5):F393-7. PubMed ID: 26084930
[TBL] [Abstract][Full Text] [Related]
14. Identification of glomerular and podocyte-specific genes and pathways activated by sera of patients with focal segmental glomerulosclerosis.
Otalora L; Chavez E; Watford D; Tueros L; Correa M; Nair V; Ruiz P; Wahl P; Eddy S; Martini S; Kretzler M; Burke GW; Fornoni A; Merscher S
PLoS One; 2019; 14(10):e0222948. PubMed ID: 31581251
[TBL] [Abstract][Full Text] [Related]
15. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis.
Daehn I; Casalena G; Zhang T; Shi S; Fenninger F; Barasch N; Yu L; D'Agati V; Schlondorff D; Kriz W; Haraldsson B; Bottinger EP
J Clin Invest; 2014 Apr; 124(4):1608-21. PubMed ID: 24590287
[TBL] [Abstract][Full Text] [Related]
16. SMPDL3b modulates insulin receptor signaling in diabetic kidney disease.
Mitrofanova A; Mallela SK; Ducasa GM; Yoo TH; Rosenfeld-Gur E; Zelnik ID; Molina J; Varona Santos J; Ge M; Sloan A; Kim JJ; Pedigo C; Bryn J; Volosenco I; Faul C; Zeidan YH; Garcia Hernandez C; Mendez AJ; Leibiger I; Burke GW; Futerman AH; Barisoni L; Ishimoto Y; Inagi R; Merscher S; Fornoni A
Nat Commun; 2019 Jun; 10(1):2692. PubMed ID: 31217420
[TBL] [Abstract][Full Text] [Related]
17. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats.
Chen CA; Hwang JC; Guh JY; Chang JM; Lai YH; Chen HC
J Lab Clin Med; 2006 Feb; 147(2):74-82. PubMed ID: 16459165
[TBL] [Abstract][Full Text] [Related]
18. Intrinsic tumor necrosis factor-α pathway is activated in a subset of patients with focal segmental glomerulosclerosis.
Chung CF; Kitzler T; Kachurina N; Pessina K; Babayeva S; Bitzan M; Kaskel F; Colmegna I; Alachkar N; Goodyer P; Cybulsky AV; Torban E
PLoS One; 2019; 14(5):e0216426. PubMed ID: 31095586
[TBL] [Abstract][Full Text] [Related]
19. The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics.
Meliambro K; Wong JS; Ray J; Calizo RC; Towne S; Cole B; El Salem F; Gordon RE; Kaufman L; He JC; Azeloglu EU; Campbell KN
J Biol Chem; 2017 Dec; 292(51):21137-21148. PubMed ID: 28982981
[TBL] [Abstract][Full Text] [Related]
20. Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte.
Heymann J; Winkler CA; Hoek M; Susztak K; Kopp JB
Nephrol Dial Transplant; 2017 Jan; 32(suppl_1):i65-i70. PubMed ID: 28391347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
